Randomized trial of community treatment with azithromycin and ivermectin mass drug administration for control of scabies and impetigo

Marks, Michael, Toloka, Hilary, Baker, Ciara, Kositz, Christian, Asugeni, James, Puiahi, Elliot, Asugeni, Rowena, Azzopardi, Kristy, Diau, Jason, Kaldor, John M., Romani, Lucia, Redman-MacLaren, Michelle, MacLaren, David, Solomon, Anthony W., Mabey, David C.W., and Steer, Andrew C. (2019) Randomized trial of community treatment with azithromycin and ivermectin mass drug administration for control of scabies and impetigo. Clinical Infectious Diseases, 68 (6). pp. 927-933.

[img]
Preview
PDF (Published Version) - Published Version
Available under License Creative Commons Attribution.

Download (167kB) | Preview
View at Publisher Website: https://doi.org/10.1093/cid/ciy574
 
7


Abstract

Background. Scabies is a public health problem in many countries, with impetigo and its complications important consequences. Ivermectin based mass drug administration (MDA) reduces the prevalence of scabies and, to a lesser extent, impetigo. We studied the impact of co-administering azithromycin on the prevalence of impetigo and antimicrobial resistance.

Methods. Six communities were randomized to receive either ivermectin-based MDA or ivermectin-based MDA co-administered with azithromycin. We measured scabies and impetigo prevalence at baseline and 12 months. We collected impetigo lesions swabs at baseline, 3 and 12 months to detect antimicrobial resistance.

Results. At baseline, scabies and impetigo prevalences were 11.8% and 10.1% in the ivermectin-only arm and 9.2% and 12.1% in the combined treatment arm. At 12 months, the prevalences had fallen to 1.0% and 2.5% in the ivermectin-only arm and 0.7% and 3.3% in the combined treatment arm. The proportion of impetigo lesions containing Staphylococcus aureus detected did not change (80% at baseline vs 86% at 12 months; no significant difference between arms) but the proportion containing pyogenic streptococci fell significantly (63% vs 23%, P < .01). At 3 months, 53% (8/15) of S. aureus isolates were macrolide-resistant in the combined treatment arm, but no resistant strains (0/13) were detected at 12 months.

Conclusions. Co-administration of azithromycin with ivermectin led to similar decreases in scabies and impetigo prevalence compared to ivermectin alone. The proportion of impetigo lesions containing pyogenic streptococci declined following MDA. There was a transient increase in the proportion of macrolide-resistant S. aureus strains following azithromycin MDA.

Item ID: 60945
Item Type: Article (Research - C1)
ISSN: 1537-6591
Copyright Information: © The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Funders: Wellcome Trust, International Trachoma Initiative
Date Deposited: 19 Nov 2019 00:57
FoR Codes: 11 MEDICAL AND HEALTH SCIENCES > 1117 Public Health and Health Services > 111799 Public Health and Health Services not elsewhere classified @ 100%
SEO Codes: 92 HEALTH > 9204 Public Health (excl. Specific Population Health) > 920499 Public Health (excl. Specific Population Health) not elsewhere classified @ 100%
Downloads: Total: 7
Last 12 Months: 7
More Statistics

Actions (Repository Staff Only)

Item Control Page Item Control Page